This profile was last updated on .
Is this you? Claim your profile.
(193 Total References)
Creabilis - News Detail
George F. Horner III, Chairman of Creabilis said: "We are delighted that Eliot has joined Creabilis.
Creabilis - Board of Directors
George Horner | Chairman
has over 40 years industry experience gained with both biotech and big pharma companies.
He was most recently the CEO of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in late 2008.
Prior to joining Prestwick, George Horner was the CEO of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for $1.9 billion in 2005.
George Horner also worked for Ligand Pharmaceuticals following a successful career at Abbott Laboratories where his final position was as President of the company's business in Canada.
has also acted as an adviser to a number of specialist life science investors in recent years.
George Horner ...
George Horner III
George Horner III
Pharmaceutical/biopharmaceutical executive with over 40 years of experience in the industry
Currently, Mr. Horner is a biotech executive consultant for several private companies in the United States and Europe.
Previous, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington's Disease patients.
Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion.
has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories
and E.R. Squibb across 4 continents, worldwide.
Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg, Chairman of the Board of Omthera Pharmaceuticals of Bedminster, New Jersey, USA, and member of the Durata Therapeutics board of directors.
DBV Technologies Elects ...
DBV Technologies Elects George Horner as Non-executive Chairman of the Board of Directors to Advance the Clinical Development of VIASKINÂ® Peanut, the Worldâ€™s First Epicutaneous Skin Patch for Desensitization of Peanut Allergy
PARIS--(BUSINESS WIRE)--DBV Technologies, an emerging biotechnology company, announced today that its board of directors has elected George F. Horner III as non-executive chairman, effective immediately.
Endo Pharmaceuticals Appoints New Independent Outside Director
CHADDS FORD, Pa., Aug. 9 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), a specialty pharmaceutical company with market leadership in pain management, today announced the appointment of George F. Horner III to its board of directors.Horner, the former chief executive officer and director of Vicuron Pharmaceuticals Inc., replaces Joseph T. O'Donnell, Jr., who has resigned.
..."We are delighted to welcome to the Endo board an executive with the kind of broad-based pharmaceutical industry experience that George Horner brings, and we look forward to his counsel as Endo continues its growth as a leading specialty pharmaceutical company," said Peter A. Lankau, president and chief executive officer.
...Horner was the president and chief executive officer and a member of the board of directors of Vicuron Pharmaceuticals Inc. from 1996 until its acquisition by Pfizer Inc. in September 2005.Prior to joining Vicuron, Horner was corporate vice president of Ligand Pharmaceuticals from 1993 to 1995.He also served in a number of executive positions during his 17 years at Abbott Laboratories from 1976 to 1993, including president, Canada; regional director, Latin America; general manager, Mexico; general manager, Southern Africa Region; and regional manager, Southeast Asia.Horner began his career in the pharmaceutical industry at E.R. Squibb, Inc., where he served in a number of sales and product management positions.